| 项目编号 |
PRJCA040041 |
| 项目标题 |
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial |
| 涉及领域 |
Medical |
| 数据类型 |
Whole genome sequencing
Transcriptome or Gene expression
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
This multicenter, phase II trial (CHESS) evaluated the safety and efficacy of zanubrutinib plus rituximab induction therapy followed by shortened chemoimmunotherapy in previously untreated mantle cell lymphoma (MCL) patients. The results showed a high complete response (CR) rate of 88% at the completion of the induction phase, with a 2-year progression-free survival and overall survival rate of 85% and 90%, respectively. Transcriptomic analyses identified three MCL molecular subtypes with distinct treatment responses, providing insights for future personalized treatment strategies. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2025-05-12 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| National Natural Science Foundation of China
|
|
82230001
|
|
| National Natural Science Foundation of China
|
|
82270199
|
|
| Guangzhou Science and Technology Program
|
|
2024B03J1291
|
|
| National Key Research and Development Program
|
|
2022YFC2502602
|
|
| Sun Yat-Sen University Clinical Research 5010 Program
|
|
2020009
|
|
| Clinical Oncology Foundation of Chinese Society of Clinical Oncology
|
|
Y-SY2021ZD-0110
|
|
| China National Postdoctoral Program for Innovative Talents
|
|
BX20240445
|
|
|
|
| 提交者 |
Qingqing
Cai (caiqq@sysucc.org.cn)
|
| 提交单位 |
Sun Yat-sen University Cancer Center |
| 提交日期 |
2025-05-12 |
